Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Here we show that the size of the EGFR T790M-positive clone impacts response to osimertinib. T790M subclonality, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaclova, Tereza, Grazini, Ursula, Ward, Lewis, O’Neill, Daniel, Markovets, Aleksandra, Huang, Xiangning, Chmielecki, Juliann, Hartmaier, Ryan, Thress, Kenneth S., Smith, Paul D., Barrett, J. Carl, Downward, Julian, de Bruin, Elza C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979775/
https://www.ncbi.nlm.nih.gov/pubmed/33741979
http://dx.doi.org/10.1038/s41467-021-22057-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979775/
https://www.ncbi.nlm.nih.gov/pubmed/33741979
http://dx.doi.org/10.1038/s41467-021-22057-8

Ejemplares similares